Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy.
Permanent neonatal diabetes (PND) can be caused by mutations in the transcription factors insulin promoter factor (IPF)-1, eukaryotic translation initiation factor-2alpha kinase 3 (EIF2AK3), and forkhead box-P3 and in key components of insulin secretion: glucokinase (GCK) and the ATP-sensitive K(+)...
Asıl Yazarlar: | Sagen, J, Raeder, H, Hathout, E, Shehadeh, N, Gudmundsson, K, Baevre, H, Abuelo, D, Phornphutkul, C, Molnes, J, Bell, G, Gloyn, A, Hattersley, A, Molven, A, Søvik, O, Njølstad, P |
---|---|
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
2004
|
Benzer Materyaller
-
Functional effects of mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), causing neonatal diabetes, and response to sulfonylurea therapy.
Yazar:: Proks, P, ve diğerleri
Baskı/Yayın Bilgisi: (2006) -
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Yazar:: Pearson, E, ve diğerleri
Baskı/Yayın Bilgisi: (2006) -
Kir6.2 mutations causing neonatal diabetes provide new insights into Kir6.2-SUR1 interactions.
Yazar:: Tammaro, P, ve diğerleri
Baskı/Yayın Bilgisi: (2005) -
Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype.
Yazar:: Flanagan, SE, ve diğerleri
Baskı/Yayın Bilgisi: (2006) -
Neonatal diabetes - The role of KCNJ11 (Kir6.2)
Yazar:: Tammaro, P
Baskı/Yayın Bilgisi: (2007)